USD10
Actions ZBIO
À propos de Zenas BioPharmaZenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
USD10
Actions ZBIO
À propos de Zenas BioPharmaZenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
Données insuffisantes
Capitalisation boursière
1,05 Md $US
PRIX D'OUVERTURE
19,23 $US
BAS (1 an)
6,11 $US
ÉLEVÉ (1 an)
44,60 $US
BAS (24 h)
17,20 $US
ÉLEVÉ (24 h)
19,35 $US
Volume (24 h)
3,37 M $US
1 322,55 %
Historique des prix
Time | Price | Change |
|---|---|---|
Aujourd'hui | 19,23 $US | |
1 jour | 17,53 $US | |
1 semaine | 21,77 $US | |
1 mois | 25,57 $US | |
1 an | 7,90 $US |